Loading...

Brilliant Violet 421™ anti-mouse/human CD45R/B220 Antibody

Pricing & Availability
Clone
RA3-6B2 (See other available formats)
Regulatory Status
RUO
Other Names
B220
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RA3-6B2_BV421_032911
C57BL/6 mouse splenocytes were stained with CD45R/B220 (clone RA3-6B2) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • RA3-6B2_BV421_032911
    C57BL/6 mouse splenocytes were stained with CD45R/B220 (clone RA3-6B2) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).
  • RA3-6B2_BV421_CD45RB220_Antibody_2_IHC-F_080519
    C57BL/6 mouse frozen spleen sections were fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS plus 5% rat/mouse serum for 30 minutes at room temperature. Then the section was stained with 1.25 µg/ml of anti-mouse/human CD45R/B220 (clone RA3-6B2) Brilliant Violet 421™ (blue), anti-mouse CD5 (clone 53-7.3) Alexa Fluor® 594 (red), and anti-mouse F4/80 (clone BM8) Alexa Fluor® 647 (green) overnight at 4°C. The image was captured with a 10X objective.
See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
103239 125 µL 132€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103251 50 µg 194€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103240 500 µL 300€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL-Faslpr and MRL-Fasgld mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse,Human
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Abelson murine leukemia virus-induced pre-B tumor cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For immunohistochemistry on frozen tissue sections, a concentration range of 2.5 - 10 µg per ml. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro and in vivo modulation of B cell responses2-4, immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections5,6, and spatial biology (IBEX)14,15.

Application References

(PubMed link indicates BioLegend citation)
  1. Coffman RL. 1982. Immunol. Rev. 69:5. (IP)
  2. George A, et al. 1994. J. Immunol. 152:1014. (Activ)
  3. Asensi V, et al. 1989. Immunology 68:204. (Activ)
  4. Domiati-Saad R, et al. 1993. J. Immunol. 151:5936. (Activ)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Monteith CE, et al. 1996. Can. J. Vet. Res. 60:193. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Chang C L-T, et al. 2007. J. Immunol. 178:6984.
  9. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  10. Lang GL, et al. 2008. Blood 111:2158. PubMed
  11. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  12. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  13. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  14. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  15. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  2. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  3. Bi E, et al. 2018. J Clin Invest. 128:4821. PubMed
  4. Yáñez A et al. 2017. Immunity. 47(5):890-902 . PubMed
  5. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  6. Nagatake T, et al. 2019. Mucosal Immunol. 12:p1082. PubMed
  7. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  8. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  9. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  10. Argüello RJ, et al. 2018. J Cell Sci. 131:jcs214346. PubMed
  11. Powell WE, et al. 2018. Diabetologia. 61:1794. PubMed
  12. Koohy H, et al. 2018. Genome Biol. 0.879166667. PubMed
  13. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  14. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  15. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  16. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  17. Marchalot A, et al. 2020. Front Immunol. 11:780. PubMed
  18. Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed
  19. Lindner J, et al. 2014. J Immunol. 192:4483. PubMed
  20. Siegemund S, et al. 2015. PLoS One. 10:124661. PubMed
  21. Li J, et al. 2020. Elife. 9:00. PubMed
  22. Xu G, et al. 2020. Cell Rep. 32:108170. PubMed
  23. Utley A, et al. 2020. Cell Rep. 31:107815. PubMed
  24. Girón-Pérez DA, et al. 2020. J Cell Sci. 133:00:00. PubMed
  25. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  26. Mogilenko DA, et al. 2020. Immunity. 54(1):99-115.e12. PubMed
  27. Lazarian G, et al. 2021. Cancer Cell. 39(3):380-393.e8. PubMed
  28. Sano T, et al. 2021. Cell Reports. 36:109608. PubMed
  29. Verheijen M, et al. 2020. Cell Rep. 108376:33. PubMed
  30. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
  31. Huang YL, et al. 2021. Commun Biol. 4:229. PubMed
  32. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  33. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  34. Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
  35. Liu X, et al. 2022. Nat Cancer. :. PubMed
  36. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  37. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  38. Saber M, et al. 2021. J Neurosci Res. 99:1136. PubMed
  39. Wittner J, et al. 2022. Mucosal Immunol. 15:668. PubMed
  40. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  41. Lee JH, et al. 2022. Cell Rep. 38:110485. PubMed
  42. Du Y, et al. 2022. J Exp Med. 219: . PubMed
  43. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  44. Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed
  45. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  46. Byrne PO, et al. 2023. Nat Commun. 14:1494. PubMed
  47. Hao H, et al. 2023. Nat Biomed Eng. . PubMed
RRID
AB_10933424 (BioLegend Cat. No. 103239)
AB_2562905 (BioLegend Cat. No. 103251)
AB_11203896 (BioLegend Cat. No. 103240)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

B cells, T cell subset, NK cell subset

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID 5788 View all products for this Gene ID
UniProt
View information about CD45R on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 4    Revision Date: 08.05.2019

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account